Haleon's (HLN) Sector perform Rating Reaffirmed at Royal Bank Of Canada

Key Points

• Haleon's stock has been given a "sector perform" rating by Royal Bank of Canada, with a price target of GBX 370 ($4.89), indicating a potential upside of 0.95% from its current price.
• The company reported quarterly earnings of GBX 8.90 ($0.12) per share, with analysts predicting a total of 19.50 earnings per share for the current fiscal year.
• Insider transactions include a purchase of 21,300 shares by Marie-Anne Aymerich and a sale of 64,329 shares by Dawn Allen, reflecting active insider engagement with the stock.

Haleon (LON:HLN - Get Free Report)'s stock had its "sector perform" rating restated by analysts at Royal Bank Of Canada in a research report issued to clients and investors on Thursday, July 31st, MarketBeat.com reports. They presently have a GBX 370 ($4.94) price target on the stock. Royal Bank Of Canada's price objective would suggest a potential upside of 4.82% from the company's current price.

Haleon Stock Up 1.4%

Shares of LON:HLN traded up GBX 4.90 ($0.07) during midday trading on Thursday, reaching GBX 353 ($4.72). The company had a trading volume of 28,185,211 shares, compared to its average volume of 25,365,520. Haleon has a 1-year low of GBX 346.10 ($4.62) and a 1-year high of GBX 419.50 ($5.60). The stock has a market cap of £31.86 billion, a PE ratio of 29.69, a P/E/G ratio of 1.49 and a beta of 0.19. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The business's 50 day moving average price is GBX 377.97 and its 200 day moving average price is GBX 384.68.

Haleon (LON:HLN - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported GBX 8.90 ($0.12) earnings per share for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. Research analysts forecast that Haleon will post 19.5033282 EPS for the current fiscal year.

Insider Activity

In other Haleon news, insider Blathnaid Bergin acquired 6,145 shares of Haleon stock in a transaction that occurred on Friday, May 16th. The shares were bought at an average price of GBX 404 ($5.40) per share, with a total value of £24,825.80 ($33,162.97). Also, insider Dawn Allen sold 64,329 shares of the company's stock in a transaction on Monday, June 30th. The shares were sold at an average price of GBX 376 ($5.02), for a total transaction of £241,877.04 ($323,105.85). 10.74% of the stock is currently owned by insiders.

About Haleon

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.